ND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference in Boston, on Monday, March 4, 2013, at 3:30 p.m. ET.
